8-K
filed October 27, 2023, 7:59 PM ET
ticker CLRB
CIK 0001279704
regulatory
confidence high
sentiment negative
materiality 0.60
Cellectar shareholders approve 10M share increase; Nasdaq OKs compliance plan with Feb 12 deadline
Cellectar Biosciences, Inc.
- Shareholders approved amendment to increase authorized common stock from 160M to 170M shares at special meeting on Oct 25.
- Issuance proposal (conversion of Series E Preferred >19.99% of outstanding) approved with 3,318,009 votes for, 236,357 against.
- Nasdaq non-compliance with $2.5M stockholders' equity rule; plan approved; deadlines: Jan 4 warrant update, Feb 12 compliance evidence.
- Failure to demonstrate compliance by Q1 2024 filing may result in delisting; company cautions no assurance of regaining compliance.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Cellectar Biosciences, Inc.: Increased authorized common stock from 160,000,000 to 170,000,000 shares (effective 2023-10-25).
- Change
- charter amendment
- Effective
- 2023-10-25
Exact text from the filing
On October 25, 2023, Cellectar Biosciences, Inc. (the “Company”) filed a Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of the Company (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to increase the total number of authorized shares of the Company’s common stock from 160,000,000 to 170,000,000.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Cellectar Biosciences, Inc. shareholders approved Issuance Proposal – approval of issuance in excess of 19.99% of outstanding common stock upon conversion of Series E Preferred Stock at the 2023-10-25 meeting.
- Outcome
- passed
- Meeting
- 2023-10-25
Exact text from the filing
(1) approved the issuance in excess of 19.99% of the Company’s outstanding common stock upon conversion of the Series E Preferred Stock at less than the “minimum price” and which may be deemed a “change of control” under Nasdaq Listing Rule 5635 (the “Issuance Proposal”)
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Cellectar Biosciences, Inc. shareholders approved Amendment Proposal – amendment to increase authorized common stock from 160,000,000 to 170,000,000 shares at the 2023-10-25 meeting.
- Proposal
- charter amendment
- Outcome
- passed
- Meeting
- 2023-10-25
Exact text from the filing
(2) approved the amendment of the Company’s Second Amended and Restated Certificate of Incorporation, as amended, to increase the authorized common stock from 160,000,000 to 170,000,000 shares (the “Amendment Proposal”)
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Cellectar Biosciences, Inc. shareholders approved Adjournment Proposal – adjournment of the Special Meeting to solicit additional proxies if necessary at the 2023-10-25 meeting.
- Outcome
- passed
- Meeting
- 2023-10-25
Exact text from the filing
(3) approved the adjournment of the Special Meeting, if necessary in the reasonable discretion of the Company’s Board, the Chairman of the Board, the President or the Corporate Secretary to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve any of the other proposals (the “Adjournment Proposal”)
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.